All In Biotech

Drug Trial Radar · NCT07077512

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

A Single-arm, Phase II Clinical Study of Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma.

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Jan 15, 2027

Study completion Jul 15, 2027

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fifth Affiliated Hospital of Guangzhou Medical University; Guangzhou Overseas Chinese Hospital,Guangdong
First posted
Jul 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma

Conditions

  • Large B Cell Diffuse Lymphoma
  • Mantle Cell Lymphoma (MCL)
  • Follicular Lymphoma ( FL)

Interventions

  • Autoleucel (Relmacabtagene Autoleucel)Drug

    Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodepletion (fludarabine + cyclophosphamide).

  • Sintilimab (PD-1 inhibitor)Drug

    Patients will receive intravenous Sintilimab (200 mg every 3 weeks) starting on Day 28 after reinfusion, continuing until disease progression or intolerable toxicity, with a maximum duration of 1 year.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The complete response rate (CRR) at 3 monthsTime frame: Up to 3 months after Relmacabtagene Autoleucel infusion

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Universitiy Cancer Center

    Guangzhou, China · Recruiting

  • Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China · Not yet recruiting

  • Guangzhou overseas Chinese hospital

    Guangzhou, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.